Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-02-13
2010-02-16
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S212000
Reexamination Certificate
active
07662817
ABSTRACT:
Corticotropin releasing factor (CRF) antagonists of Formula (I):and its use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
REFERENCES:
patent: 6191131 (2001-02-01), He et al.
patent: 6194410 (2001-02-01), Bos et al.
patent: 6218397 (2001-04-01), Chen
patent: 6642230 (2003-11-01), Wilde et al.
patent: 7157578 (2007-01-01), Gilligan
patent: 7358252 (2008-04-01), Gilligan
patent: 2124016 (1998-12-01), None
patent: 97100192 (1999-02-01), None
patent: 99105137 (2001-01-01), None
patent: 2201929 (2003-04-01), None
patent: 2221799 (2004-01-01), None
patent: WO 95/10506 (1995-04-01), None
patent: WO 95/33750 (1995-12-01), None
patent: WO 97/35539 (1997-10-01), None
patent: WO 97/35846 (1997-10-01), None
patent: WO 97/44308 (1997-11-01), None
patent: WO 98/03510 (1998-01-01), None
patent: WO 99/01439 (1999-01-01), None
patent: WO 99/01454 (1999-01-01), None
patent: WO 99/11643 (1999-03-01), None
patent: WO 99/38868 (1999-08-01), None
patent: WO 99/51608 (1999-10-01), None
patent: WO 00/01675 (2000-01-01), None
He, Liqi, et al. 4-(1,3-dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)pyrazolo [1,5-a]-1,3,5-triazine: A Potent, Orally Bioavailable CRF1Receptor Antagonist, Journal of Medicinal Chemistry, American Chemical Society, Washington, US., vol. 43, 2000, pp. 449-456, XP002196777, ISSN: 0022-2623.
Wermuth et al.; Molecular Variations Based on Isosteric Replacement; The Practice of Medicinal Chemistry, 1996, pp. 203-237, XP 002190259.
Arato, M., et al.; Elevated CSF CRF in suicide victims; Biol Psychiatry, 1989, 25, pp. 355-359.
Banki, C.M., et al.; CSF corticotrophin-releasing factor-like immunoreactivity in depression and schizophrenia; Am. J. Psychiatry, Jul. 1987, pp. 873-877.
Berridge, C.W., et al.; A corticotropin-releasing factor antagonist reverses the stress-induced changes of exploratory behavior in mice; Hormones and Behavior, 1987, 21, pp. 393-401.
Berridge, C.W., et al.; Corticotropin-releasing factor elicits naloxone sensitive stress-like alterations in exploratory behavior in mice; Regulatory Peptides, 1986; 16; pp. 83-93.
Blalock, J.E.; A molecular basis for bidirectional communication between the immune and neuroendocrine systems; Physiological Reviews, Jan. 1989, 69(1), pp. 1-32.
Britton, K.T., et al.; Chlordiazepoxide attenuates response suppression induced by corticotrophin-releasing factor in the conflict test; Psychopharmacology, 1985, 86; pp. 170-174.
Britton, K.T., et al., Corticotropin releasing factor and amphetamine exaggerate partial agonist properties of benzodiazepine antagonist Ro 15-1788; Psychopharmacology, 1988, 94, pp. 306-311.
Britton, D.R., et al.; Intraventricular corticotrophin-releasing factor enhances behavioral effects of novelty; Life Sciences, May 12, 1982, 31(4), pp. 363-367.
Bundgard, H., Advanced Drug Delivery Reviews, 1992, 8, pp. 1-38.
Chrousos, G.P., et al.; Int. J. Obesity, 2000, 24 (Supp. 2); S50-S55.
DeSouza, E.B., et al.; Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system: An autoradiographic study; J. Neuroscience, Dec. 1985; 5(12); pp. 3189-3203.
DeSouza, E.B.; CRH defects in Alzheimer's and other neurologic diseases; Hospital Practice, Sep. 15, 1988, pp. 59-71.
Dunn, A.J., et al.; Physiological and behavioral responses to corticotrophin-releasing factor administration: is CRF a mediator of anxiety or stress responses?; Brain Research Reviews, 1990; 15, 71-100.
France, R.D., et al.; CSF corticotrophin-releasing factor-like immunoactivity in chronic pain patients with and without major depression; Biol. Psychiatry, 1988, 23, pp. 86-88.
Gilligan, P.J. et al.; J. Med. Chem.; 2000, 43, pp. 1641-1660.
Gold, P.W. et al.; Psychiatric implications of basic and clinical studies with corticotrophin-releasing factor; Am. J. Psychiatry, May 1984, 141(5), pp. 619-627.
Gold, P.W. et al., New Eng. J. Med., 1986, 314, pp. 1129.
Grigoriadis, D.E., et al.; Effects of chronic antidepressant and benzodiazepine treatment on corticotrophin-releasing-factor receptors in rat brain and pituitary; Neurophychopharmacology, 1989, 2(1); pp. 53-60.
Holsboer, F., et al.; Acth and multisteroid responses to corticotrophin-releasing factor in depressive illness: Relationship to multisteroid responses after acth stimulation and dexamethasone suppression; Psychoneuroendocrinology, 1984, 9(2), 147-160.
Koob, G.F., Stress, corticotrophin-releasing factor, and behavior; Perspectives on Behavioral Medicine, 1985, 2, pp. 39-52.
Koob, G.F., Ann. N.Y. Acad. Sci., 2000, 909, pp. 170-185.
Krogsgaard-Larsen, et al.; Design and applications of prodrugs; A textbook of Drug Design and Development; 1991, Chapter 5, pp. 113-191.
McCarthy et al.; Cuur. Pharm. Res.; 1999, 5, pp. 289-315.
Maillot, C. et al.; Gastroenterology, 2000, 119, pp. 1569-1579.
Morley, J.E. et al.; Minireview-neuropeptides: conductors of the immune orchestra; Life Sciences, 1987, 41, pp. 527-544.
Mastorakos, G., et al.; Ann. N.Y. Acad. Sci.; 2000, 900, pp. 95-106.
Nakeya, N. et al.; Chem. Pharm. Bull.; 1984, 32, pp. 692.
Nemeroff, C.B. et al.; Reduced corticotrophin releasing factor binding sites in the frontal cortex of suicide victims; Arch Gen. Psychiatry, Jun. 1988, 45, pp. 577-579.
Nemeroff, C.B.; Elevated concentrations of CFS corticotrophin-releasing factor-like immunoreactivity in depressed patients; Science; Dec. 14, 1984, 226, pp. 1342-1344.
Nemeroff, C.B., Corticotropin-releasing factor; basic and clinical studies of a neuropeptide; CRC Press, Inc. 1990, pp. 221-224.
Newport, D.J. et al.; Curr.Opin. Neurobiology, 2000, 10, pp. 211-218.
Owens, M.J. et al.; Expert Opin. Invest. Drugs; 1999, 8, pp. 1849-1858.
Remington's Pharmaceutical Sciences, 17thEd., p. 1419.
Rivier, J. et al.; Characterization of rat hypothalamic corticotrophin-releasing factor; Proc. Nat. Acad. Sci. USA, Aug. 1983, 80, pp. 4851-4855.
Sapolsky, R.M.; Hypercortisolism among socially subordinate wild baboons originates at the CNS level; Arch. Gen. Psychiatry, Nov. 1989, 46, pp. 1047-1051.
Swerdlow, N.R. et al.; Corticotropin-releasing factor poteniates acoustic startle in rats: blockage by chlordiazepoxide; Psychopharmacology, 1986, 88, pp. 147-152.
Webster, E. et al.; Ann. N.Y. Acad. Sci.; 1998, 840, pp. 21-32.
Widder, K. et al.; Ed. Academic Press; 1985; 42, pp. 309-396.
Vale, W. et al.; Characterization of a 41-risidue ovine hypothalamic peptide that stimulates secretion of corticotrophin and β-endorphin; Science, Sep. 1981, 213, 1394-1397.
Vale, W. et al.; Chemical and biological characterization of corticotrophin releasing factor; Recent Progress in Hormone Research, 1983, 39, pp. 245-270.
J. Pharmaceutical Sciences, 1988, 77, pp. 285.
Mitchell, A.J.; The Role of corticotrophin releasing factor in depressive illness: a critical review; Neurosci. Biobehav. Rev., Sep. 1998, 5, pp. 635-651, Abstract, 1 page.
Balasubramanian Venkataraman
Bristol-Myers Squibb Pharma Company
Hoffmann & Baron , LLP
LandOfFree
4-(2-Butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-y... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-(2-Butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-y..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-(2-Butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-y... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4214767